The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Early stage schizophrenia data have seen the group double in value, but there are a couple of sticking points.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?